JOSÉ ÁNGEL
GARCÍA SÁENZ
Profesor asociado de Ciencias de la Salud
![Foto de JOSÉ ÁNGEL](/img/nophoto.png)
![Foto de Washington University in St. Louis School of Medicine](/img/noimage_org.png)
Washington University in St. Louis School of Medicine
San Luis, Estados UnidosPublicaciones en colaboración con investigadores/as de Washington University in St. Louis School of Medicine (6)
2023
-
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer
Breast, Vol. 67, pp. 94-101
-
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898
2022
-
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation
The oncologist, Vol. 27, Núm. 7, pp. e561-e570
2021
-
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
Journal of the National Cancer Institute, Vol. 113, Núm. 4, pp. 443-452
2020
-
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
Annals of Oncology, Vol. 31, Núm. 9, pp. 1223-1230
2014
-
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer
Journal of Clinical Oncology, Vol. 32, Núm. 32, pp. 3626-3634